Literature DB >> 11941970

Arterial and vena caval resections combined with pancreaticoduodenectomy in highly selected patients with periampullary malignancies.

Hiroshi Nakano1, Philippe Bachellier, Jean-Christophe Weber, Elie Oussoultzoglou, Madieng Dieng, Hiroshi Shimura, Karim Boudjema, Philippe Wolf, Daniel Jaeck.   

Abstract

BACKGROUND/AIMS: To obtain a margin-negative resection and increase the indication for resection of periampullary malignancies, pancreaticoduodenectomy with a SM-PVR (superior mesenterico-portal vein resection) has been performed. However, an arterial resection, other vascular resections except SM-PVR (e.g., an inferior vena caval resection), or a metastatic tumor resection combined with pancreaticoduodenectomy has yet to be fully elucidated because of the high risk of postoperative complications and extremely poor long-term survival in patients undergoing these exceptional procedures. The present report focused on highly selected patients undergoing an arterial resection or a vena caval resection associated with pancreaticoduodenectomy.
METHODOLOGY: Besides 31 patients with periampullary tumors undergoing pancreaticoduodenectomy associated with SM-PVR in our department, a group of 4 patients underwent arterial resections and another patient underwent pancreaticoduodenectomy combined with a resection of liver metastasis together with an inferior vena caval resection. These five patients were reported in the present study.
RESULTS: A 27 year-old-woman presented pancreatic ductal adenocarcinoma of the pancreatic head and a liver metastasis in which involvements of the superior mesenterico-portal vein and the inferior vena cava were shown. Pancreaticoduodenectomy was performed with SM-PVR associated with a left hemihepatectomy combined with a segment 1 resection and an inferior vena caval resection. The patient did not present severe postoperative complications and experienced a good quality of life during 16 months after surgery. Four other patients underwent arterial resections. These arterial resections were performed only when a margin-negative resection was feasible. The superior mesenteric artery was resected and reconstructed with a Goretex graft in one patient. The right hepatic artery was resected and reconstructed with a saphenous graft in two patients. The other patient underwent a resection of the common hepatic artery and reconstruction was performed with the splenic artery. Three of the four patients presented postoperative complications but were conservatively treated. Two patients are still alive 25 months and 8 months after surgery. One patient died of sepsis 5 months after surgery, and the other died of cancer progression 19 months after surgery.
CONCLUSIONS: The indication for retropancreatic arterial resection associated with pancreaticoduodenectomy should be carefully evaluated only when a margin-negative resection can be achieved. An appropriate bypass method of arterial reconstruction should be selected because a direct end-to-end anastomosis is not always feasible. Hepatectomy for metastases of pancreatic ductal carcinoma should be also regarded as an exceptional procedure.

Entities:  

Mesh:

Year:  2002        PMID: 11941970

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  10 in total

1.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

2.  Pancreatic resection for pancreatic cancer.

Authors:  Jeannine Bachmann; Christoph W Michalski; Marc E Martignoni; Markus W Büchler; Helmut Friess
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

3.  Assessment of hepatic arterial anatomy in keeping with preservation of the vasculature while performing pancreatoduodenectomy: an opinion.

Authors:  Sung Hoon Yang; Yong Hu Yin; Jin-Young Jang; Seung Eun Lee; Jin Wook Chung; Kyung-Suk Suh; Kuhn Uk Lee; Sun-Whe Kim
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.352

4.  Implications of the presence of an aberrant right hepatic artery in patients undergoing pancreaticoduodenectomy.

Authors:  Ashwin Rammohan; Ravichandran Palaniappan; Anbalagan Pitchaimuthu; Kamalakannan Rajendran; Senthil Kumar Perumal; Kesavan Balaraman; Ravi Ramasamy; Jeswanth Sathyanesan; Manoharan Govindan
Journal:  World J Gastrointest Surg       Date:  2014-01-27

Review 5.  Surgical treatment for advanced pancreatic cancer.

Authors:  Hyung Jun Kwon; Sang Geol Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-08-31

6.  [Reconstruction of visceral arteries with homografts in excision of the pancreas].

Authors:  U Settmacher; J M Langrehr; I Husmann; R Eisele; M Bahra; M Heise; P Neuhaus
Journal:  Chirurg       Date:  2004-12       Impact factor: 0.955

7.  Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results.

Authors:  Satoshi Hirano; Satoshi Kondo; Takashi Hara; Yoshiyasu Ambo; Eiichi Tanaka; Toshiaki Shichinohe; On Suzuki; Kazuaki Hazama
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

8.  Results of vascular resections during pancreatectomy from two European centres: an analysis of survival and disease-free survival explicative factors.

Authors:  M Adham; D F Mirza; F Chapuis; A D Mayer; S R Bramhall; C Coldham; J Baulieux; J Buckels
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

9.  Right gastro-omental artery reconstruction after pancreaticoduodenectomy for subtotal esophagectomy and gastric pull-up.

Authors:  Masayuki Okochi; Kazuki Ueda; Takao Sakaba; Akira Kenjo; Mitsukazu Gotoh
Journal:  Int J Surg Case Rep       Date:  2015-08-18

10.  Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas.

Authors:  Thomas Zacharias; Daniel Jaeck; Elie Oussoultzoglou; Agnes Neuville; Philippe Bachellier
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.